Abstract：
Sweden is a country with a low prevalence of human lymphotropic T-cell virus (HTLV) infection, estimated at < 0.005%, but the infection rate is notably higher in specific risk groups such as HTLV-2 among intravenous drug users (IVDU) and people originating from HTLV-1 highly endemic areas. Thus, in the most recent study from 2012, the prevalence of HTLV-2 among IVDU in Stockholm was 3.2%. However, much of the epidemiological data on HTLV in Sweden stems from studies conducted primarily between the 1990s and 2007, and the impact of migration to Sweden during the past 15 years has not been evaluated. Despite Sweden\'s status as a country with generally low prevalence of HTLV, it is prudent to anticipate and prepare for several potential challenges associated with HTLV infection in the future. Proactive measures to enhance awareness, alongside strategies to curtail transmission and mitigate complications, are crucial for addressing this relatively rare, but significant health issue. In this work, we review the current epidemiological knowledge about HTLV in Sweden and discuss future Swedish perspectives.
摘要：
瑞典是人类嗜淋巴细胞T细胞病毒（HTLV）感染率较低的国家，估计<0.005%，但是，在静脉吸毒者（IVDU）和来自HTLV-1高流行地区的人群中，HTLV-2等特定风险人群的感染率明显较高。因此，在2012年的最新研究中,斯德哥尔摩IVDU中HTLV-2的患病率为3.2%.然而,有关瑞典HTLV的许多流行病学数据主要来自1990年代至2007年之间进行的研究，过去15年中移民到瑞典的影响尚未得到评估。尽管瑞典是一个HTLV患病率普遍较低的国家，谨慎的做法是预测和应对未来与HTLV感染相关的几个潜在挑战.采取积极措施提高认识,除了减少传播和减轻并发症的策略，对于解决这个相对罕见的问题至关重要，但重大的健康问题。在这项工作中,我们回顾了瑞典目前关于HTLV的流行病学知识，并讨论了瑞典未来的观点。
